Loading...
XETRNN6
Market cap17mUSD
Dec 23, Last price  
1.32EUR
1D
-0.75%
1Q
-26.26%
Jan 2017
43.31%
IPO
-27.87%
Name

NanoRepro AG

Chart & Performance

D1W1MN
XETR:NN6 chart
P/E
—
P/S
5.25
EPS
—
Div Yield, %
11.35%
Shrs. gr., 5y
8.43%
Rev. gr., 5y
3.39%
Revenues
3m
-91.56%
67,321226,800313,841831,533934,8851,041,7061,044,999607,6671,852,3401,971,8892,748,5411,218,31316,929,408162,723,12338,488,2373,246,673
Net income
0k
P
000000-27,000-1,175,854-551,675-734,075-289,619-1,188,5831,694,94929,723,387-3,724,2370
CFO
-10m
L
-783,000-548,000-934,599-769,699-1,144,899-257,600-612,400-1,122,8008,161,89913,149,600-10,263,600
Dividend
Jun 16, 20230.15 EUR/sh

Profile

NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. The company offers rapid diagnostic tests, including allergy, family planning, and preventive healthcare line products; point of care testing products for hospitals and medical practices for detection of HIV, human cardiac Troponin I, D-dimer, streptococci antigen, influenza type A and B antigens, and microalbumin; and immunochromatographic lateral flow tests for the diagnostic detection of biomarkers, as well as rapid SARS-CoV-2 antibody test and corona antigen rapid test. It also provides food supplements for men and women through online shops, as well as through pharmacies. The company is headquartered in Marburg, Germany.
URL
https://www.nanorepro.com/
IPO date
Oct 09, 2012
Employees
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,247
-91.56%
38,488
-76.35%
162,723
861.19%
Cost of revenue
5,851
28,587
108,975
Unusual Expense (Income)
NOPBT
(2,604)
9,901
53,748
NOPBT Margin
25.73%
33.03%
Operating Taxes
(640)
9,033
Tax Rate
16.81%
NOPAT
(2,604)
10,542
44,715
Net income
(3,724)
-112.53%
29,723
1,653.64%
Dividends
(1,934)
(6,452)
Dividend yield
Proceeds from repurchase of equity
(438)
19,896
BB yield
Debt
Debt current
1
150
Long-term debt
Deferred revenue
Other long-term liabilities
409
860
1,988
Net debt
(19,305)
(31,285)
(27,893)
Cash flow
Cash from operating activities
(10,264)
13,150
8,162
CAPEX
(3,306)
(1)
Cash from investing activities
(2,028)
(3,306)
(1)
Cash from financing activities
(2,372)
(6,602)
18,694
FCF
(2,922)
36,992
13,501
Balance
Cash
20,621
31,260
28,018
Long term investments
(1,316)
25
25
Excess cash
19,143
29,361
19,907
Stockholders' equity
18,120
47,433
57,609
Invested Capital
22,664
18,881
38,591
ROIC
36.68%
188.41%
ROCE
20.49%
80.17%
EV
Common stock shares outstanding
12,713
12,904
12,904
Price
Market cap
EV
EBITDA
(2,583)
9,901
53,748
EV/EBITDA
Interest
52
Interest/NOPBT
0.10%